Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Derivation of mimetic γδ T cells endowed with cancer recognition receptors from reprogrammed γδ T cell

9 May 2019

Abstract excerpt

Using induced pluripotent stem cells (iPSCs) to derive chimeric antigen receptor-modified T (CAR-T) cells has great industrial potential. A previous study used αβ T cell-derived CAR-modified iPSCs to produce CAR-T cells. However, these αβ T cells are restricted to autologous use and only recognize single cancer antigen. To make CAR-T alternative for allogeneic use, we reprogrammed γδ T cell into iPSCs (γδ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31071196
DOI: 10.1371/journal.pone.0216815

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Derivation of mimetic γδ T cells endowed with cancer recognition receptors from reprogrammed γδ T cellPMID 31071196Read ↗

Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapySemantic proximity Read ↗

iPSC-Derived Natural Killer Cells for Cancer ImmunotherapySemantic proximity Read ↗

An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer CellsSemantic proximity Read ↗

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospectsSemantic proximity Read ↗

Multiplexed iPSC platform for advanced NK cell immunotherapiesSemantic proximity Read ↗

Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.Semantic proximity Read ↗

Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and ChallengesSemantic proximity Read ↗

Engineered iPSC ‐derived natural killer cells: recent innovations in translational innate anti‐cancer immunotherapySemantic proximity Read ↗

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapiesSemantic proximity Read ↗

Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapySemantic proximity Read ↗

Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer ImmunotherapySemantic proximity Read ↗

Genetically stable multi-gene edited iPSCs-derived NK cells for enhanced cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.